Cerenome Appoints Ronnie Andrews as Chief Business Officer to Advance CNSide Diagnostics Commercial Strategy

2026-11-10

Investivoq

Cerenome has appointed Ron Andrews as Chief Business Officer to enhance its business development and commercial strategy.

Investivoq AI Summary

Cerenome, Inc. has appointed Ron Andrews as the Chief Business Officer, a newly created role, while he remains on the Board of Directors. Andrews, who has over 35 years of experience in the diagnostics industry, will focus on enhancing Cerenome's business development and commercial strategies, particularly the CNSide® Diagnostics platform and forming strategic partnerships. He has a successful track record in translating diagnostic technologies into commercial achievements and has previously held significant leadership positions at companies like Clarient and Life Technologies. Cerenome is dedicated to advancing integrated CNS oncology solutions, combining precision diagnostics, therapeutics, and AI to improve patient outcomes.

Potential Positives

Appointment of Ron "Ronnie" Andrews as Chief Business Officer enhances Cerenome's leadership team and strategic direction in advancing its business development efforts.
Mr. Andrews brings over 35 years of industry experience and a proven track record of raising substantial capital and achieving significant company exits, which may facilitate Cerenome's growth and partnership opportunities.
His focus on expanding the adoption of the CNSide® Diagnostics platform highlights the company's commitment to improving patient care in CNS oncology.
Strengthening the executive team and strategic partnerships is expected to support Cerenome's integrated platform for diagnostics and therapeutics, potentially creating long-term shareholder value.

Potential Negatives

The press release highlights a newly created Chief Business Officer position, suggesting potential challenges in current leadership structure and strategic direction.
There is a reliance on forward-looking statements, which may raise uncertainty regarding the company's future performance and market success.
The mention of previous roles and accomplishments of Mr. Andrews might indicate the company's need to bolster its executive leadership amid a competitive market landscape.

FAQ

Who is the new Chief Business Officer of Cerenome?

Ron "Ronnie" Andrews has been appointed as the Chief Business Officer at Cerenome.

What will Ronnie Andrews focus on in his new role?

He will advance Cerenome’s business development and commercial strategy, particularly for the CNSide® Diagnostics platform.

What experience does Ronnie Andrews bring to Cerenome?

He has over 35 years in the diagnostics industry, raising over $600 million and contributing to exits worth over $15 billion.

What is the CNSide® Diagnostics platform?

The CNSide platform combines cellular and molecular testing for the detection and monitoring of CNS cancers.

Where can I find more information about Cerenome?

More information is available on Cerenome's official website at https://www.cerenome.com.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$CNSY Hedge Fund Activity

We have seen 1 institutional investors add shares of $CNSY stock to their portfolio, and 3 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

GEODE CAPITAL MANAGEMENT, LLC added 5,588 shares (+7.3%) to their portfolio in Q3 2026, for an estimated $10,449
BARCLAYS PLC removed 24 shares (-25.0%) from their portfolio in Q3 2026, for an estimated $44
CITIGROUP INC removed 17 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $31
CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD removed 7 shares (-58.3%) from their portfolio in Q3 2026, for an estimated $13
ASHTON THOMAS PRIVATE WEALTH, LLC added 0 shares (+0.0%) to their portfolio in Q3 2026, for an estimated $0
SBI SECURITIES CO., LTD. added 0 shares (+0.0%) to their portfolio in Q3 2026, for an estimated $0

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

Full Release

HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence, today announced the appointment of Ron “Ronnie” Andrews as Chief Business Officer, a newly created position. Mr. Andrews will continue to serve on the Company’s Board of Directors.

In his new role, Mr. Andrews will focus on advancing Cerenome’s business development and commercial strategy, with an emphasis on expanding adoption of the CNSide ^® Diagnostics platform and developing strategic partnerships. He brings more than 35 years of diagnostics industry leadership experience, helping companies raise more than $600 million in capital and contributing to strategic exits totaling more than $15 billion.

“Ronnie has extensive experience translating diagnostic technologies into commercial success, along with a deep understanding of the clinical, reimbursement, and operational requirements that drive adoption,” said Marc H. Hedrick, M.D., Cerenome’s President and Chief Executive Officer. “Through his service on our Board, he is well-versed in our strategy and the value of CNSide. His addition to our executive team strengthens our ability to expand our diagnostics business and pursue partnerships that support our integrated CNS oncology platform.”

“My career has featured an unwavering commitment to the democratization of diagnostic technologies, empowering community oncologists and pathologists with the tools they need for precise, timely patient care,” said Mr. Andrews. “CNSide addresses an important need in the detection and longitudinal monitoring of CNS cancers, and the opportunity to broaden its use in clinical practice is clear and meaningful. I look forward to working with the Cerenome team to build commercial relationships, strategically expand our industry-leading CNS testing platform and advance the Company’s growth strategy.”

Mr. Andrews is the founder and Managing Partner of The Bethesda Group Advisors, a strategic advisory firm serving life science, molecular diagnostics and genomics companies. He previously served as Chief Executive Officer and Vice Chairman of Clarient, where he led its transformation from a start-up digital pathology device company into a molecular pathology services business. Under his leadership, Clarient achieved 24 consecutive quarters of sequential revenue growth and was acquired by GE Healthcare for $587 million. He subsequently led Clarient within GE Healthcare and served on GE Healthcare’s executive staff.

At Life Technologies and Thermo Fisher Scientific, Mr. Andrews led the Genetic Sciences Division, integrating sequencing and molecular testing technologies into a $2+ billion business led by the industry’s first “gene-chip based” molecular profiling test for cancer therapy selection testing. As President and Chief Executive Officer of Oncocyte, he managed the company’s transition from a blood-based testing research organization to a precision diagnostics business focused on treatment decisions and blood-based monitoring in oncology and transplant. Earlier in his career, he held sales, marketing, and global commercial positions with Roche, Immucor, and Abbott.

He previously served on the Board of Governors for CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology, and currently holds board positions with leading molecular diagnostics and emerging AI diagnostic companies including Agendia, SimBioSys, SMi Systems and Dxcover Ltd. Mr. Andrews holds a Bachelor of Science in Biology from Wofford College, where he serves as a Trustee.

About Cerenome

Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The CNSide® CSF diagnostics platform combines cellular and molecular testing to support the detection, characterization, and longitudinal assessment of cancers involving the CNS.

Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com .

Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.

Investor Contact

CORE IR
IR@cerenome.com